MedTrace Logo

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

NCT01079234 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 493

Last updated 2017-02-09

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.

Conditions

Interventions

DRUG

insulin degludec

Injected subcutaneously (under the skin) once daily

DRUG

insulin glargine

Insulin glargine injected subcutaneously (under the skin) once daily

DRUG

insulin aspart

At least three daily doses at meal-time

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-11-30
Completion
2011-05-31

Countries

  • United States
  • Belgium
  • Germany
  • Greece
  • Norway
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079234 on ClinicalTrials.gov